In the early stages of tumor progression, the treatment of tumor-bearing animals with immunomodulatory antibodies targeting PD-L1 or PD-1 triggers effector T-cell responses, which can induce tumor cell death (33). This evidence concerns the gene RPL17 and neoplasm.